Identification and Antifungal Therapy of Candida auris

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Fungal Pathogens".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 72

Special Issue Editor

E-Mail Website
Guest Editor
Medical Microbiology, Clinical Centre, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary
Interests: antifungal susceptibility testing; antifungal pharmacodynamics; epidemiology of Candida species; animal models
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Candida auris is a critical-priority fungi according to the World Health Organization. It was first discovered in a woman's ear in Japan in 2009, but within 10 years, it has spread quickly across the globe. C. auris can be misidentified as other types of fungi unless specialized laboratory technology is used. This misidentification might lead to a patient getting the wrong treatment. C. auris spreads easily in hospitals and nursing homes among people who are already sick, have lines, tubes and drains entering their body and previously received antibiotics or antifungals.

C. auris isolates found across the globe have been genetically grouped into six clades. Clades are important because the susceptibility of C. auris isolates to antifungal drugs is variable and can depend on the clade. The resistant rate to fluconazole is high, and to amphotericin B it is lower. Currently, echinocandins are the recommended initial therapy for the treatment of invasive C. auris infections. The clade-specific mortality is still high, especially among patients with COVID-19-associated infections where a mortality rate of 66% was noticed  in the South American clade.

Prof. Dr. László Majoros
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • epidemiology
  • clade-specific virulence
  • clinical outcome
  • new therapeutic strategies

Published Papers

This special issue is now open for submission.
Back to TopTop